Trader consensus implies an 89% probability of no hantavirus vaccine approval by December 31, 2026, driven by the absence of any candidates in late-stage clinical trials amid a recent multi-country outbreak linked to cruise ship travel. As of May 2026, the CDC and WHO report eight confirmed or suspected cases with three deaths, yet confirm no licensed vaccine or specific antiviral exists globally, with care limited to supportive measures. Promising efforts—like DNA vaccines showing neutralizing antibodies in Phase 1 trials for Andes and Hantaan viruses, preclinical mRNA candidates from Moderna, and new antigens from University of Bath researchers—remain in early development, requiring years for Phase 3 trials and FDA review without accelerated funding akin to Operation Warp Speed. Upcoming data from ongoing Phase 2a immunogenicity studies may inform progress, but historical timelines for rare pathogens reinforce the unlikelihood of 2026 approval.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$78,564 Vol.
$78,564 Vol.
Dec 31, 2026
$78,564 Vol.
$78,564 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus implies an 89% probability of no hantavirus vaccine approval by December 31, 2026, driven by the absence of any candidates in late-stage clinical trials amid a recent multi-country outbreak linked to cruise ship travel. As of May 2026, the CDC and WHO report eight confirmed or suspected cases with three deaths, yet confirm no licensed vaccine or specific antiviral exists globally, with care limited to supportive measures. Promising efforts—like DNA vaccines showing neutralizing antibodies in Phase 1 trials for Andes and Hantaan viruses, preclinical mRNA candidates from Moderna, and new antigens from University of Bath researchers—remain in early development, requiring years for Phase 3 trials and FDA review without accelerated funding akin to Operation Warp Speed. Upcoming data from ongoing Phase 2a immunogenicity studies may inform progress, but historical timelines for rare pathogens reinforce the unlikelihood of 2026 approval.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:39 AM ET
Volume
$78,564End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus implies an 89% probability of no hantavirus vaccine approval by December 31, 2026, driven by the absence of any candidates in late-stage clinical trials amid a recent multi-country outbreak linked to cruise ship travel. As of May 2026, the CDC and WHO report eight confirmed or suspected cases with three deaths, yet confirm no licensed vaccine or specific antiviral exists globally, with care limited to supportive measures. Promising efforts—like DNA vaccines showing neutralizing antibodies in Phase 1 trials for Andes and Hantaan viruses, preclinical mRNA candidates from Moderna, and new antigens from University of Bath researchers—remain in early development, requiring years for Phase 3 trials and FDA review without accelerated funding akin to Operation Warp Speed. Upcoming data from ongoing Phase 2a immunogenicity studies may inform progress, but historical timelines for rare pathogens reinforce the unlikelihood of 2026 approval.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$78,564End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Trader consensus implies an 89% probability of no hantavirus vaccine approval by December 31, 2026, driven by the absence of any candidates in late-stage clinical trials amid a recent multi-country outbreak linked to cruise ship travel. As of May 2026, the CDC and WHO report eight confirmed or suspected cases with three deaths, yet confirm no licensed vaccine or specific antiviral exists globally, with care limited to supportive measures. Promising efforts—like DNA vaccines showing neutralizing antibodies in Phase 1 trials for Andes and Hantaan viruses, preclinical mRNA candidates from Moderna, and new antigens from University of Bath researchers—remain in early development, requiring years for Phase 3 trials and FDA review without accelerated funding akin to Operation Warp Speed. Upcoming data from ongoing Phase 2a immunogenicity studies may inform progress, but historical timelines for rare pathogens reinforce the unlikelihood of 2026 approval.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions